References
- Lind JN, Lovegrove MC, Geller AI, et al. Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a cross-sectional analysis. J Gen Intern Med. 2021;36(9):2909–2911.
- Temple C, Hoang R, Hendrickson RG. Toxic effects from ivermectin use associated with prevention and treatment of COVID-19. N Engl J Med. 2021;385(23):2197–2198.
- Makenga Bof JC, Muteba D, Mansiangi P, et al. Analysis of severe adverse effects following community-based ivermectin treatment in the democratic republic of Congo. BMC Pharmacol Toxicol. 2019;20(1):49.
- Johnson-Arbor K. Ivermectin: a mini-review. Clin Toxicol (Phila). 2022;60(5):571–575.
- Durvet: ivermectin injection for cattle & swine. Blue Springs (MO): Durvet Inc; 2021 [cited 2022 Oct 9]. Available from: https://www.durvet.com/wp-content/uploads/2017/09/ivermectin-inj_50mL_bimeda_0216.pdf
- Durvet: ivermectin paste. Blue Springs (MO): Durvet Inc; 2021 [cited 2022 Oct 9]. Available from: https://www.durvet.com/wp-content/uploads/2017/12/ivermectin-paste_box_6.08g_0221_e.pdf
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Deng J, Zhou F, Ali S, et al. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021;114(10):721–732.
- Wu YK, Chang CH, Yu JH, et al. Intentional avermectin pesticide ingestion: a retrospective multicenter study. Clin Toxicol (Phila). 2022;60(10):1099–1105.
- Farah R, Kazzi Z, Brent J, et al. Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project. Clin Toxicol. 2022;60(8):942–946.
- Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2003;2 Suppl 1(Suppl 1):S8.